Rheinmetall's €80.5bn Backlog Faces Its Moment of Truth as Boxer Decision Looms

Rheinmetall shares rise 2.8% on new Kassel hub, but Boxer order and backlog growth remain key for investors.

The defence contractor's shares climbed 2.8 percent on Thursday, pushing the stock back toward its 100-day moving average of €1,191.85 — a technical threshold that had been breached during a months-long slide. The rebound came as Rheinmetall unveiled plans for a new logistics and technology hub at Kassel-Calden airport, a €260m-plus investment backed by a double-digit million-euro subsidy from the state of Hesse, complete with a drone testing facility.

The timing is no coincidence. Management is using a packed investor calendar — Thursday's DZ Bank "Expert Day" in Bremen, followed by the Berenberg Stockholm Seminar on 1 September — to make the case that an enormous order pipeline will translate into durable revenue growth. The backlog currently stands at €80.5bn, and market expectations point to that figure crossing the €100bn threshold by the end of the 2026 financial year.

The Boxer contract: everything hinges on Berlin

Chief executive Armin Papperger reiterated on 13 August that the Bundeswehr's long-awaited Boxer armoured vehicle order should be signed before year-end. Rheinmetall's share of the total contract value is projected at roughly €12.4bn. But this remains a management target rather than a signed deal, and completion depends on political and budgetary processes that have proven slippery before.

A successful close would meaningfully expand the backlog and cement the growth narrative for the latter half of the decade. A slip into 2027 or beyond, however, would hand fresh ammunition to the sceptics — and the market has already demonstrated how sensitively it reacts to delay signals. Despite the recent recovery, the stock remains 41 percent below its 52-week high of €2,007.

A steady drumbeat of smaller wins

While the Boxer decision dominates the narrative, a series of smaller contract announcements has been quietly reinforcing the growth story. On Tuesday, the federal procurement office BAIUDBw placed the first call-off for a modular camp for 2,000 soldiers in Lithuania — €250m for construction and setup, plus roughly €40m per year in ongoing operations. Mid-August brought a follow-on order for mobile field hospitals, lifting the total value of that programme to over €600m.

Rheinmetall is also broadening its technological footprint. A demonstration with Hensoldt roughly a week ago showcased the integration of passive sensor technology into a modern air defence system, while a new competence centre for autonomous systems in Britain is designed to deepen collaboration with Canada. These moves, alongside the Kassel-Calden investment, point to a group positioning its capacity for a structurally higher level of demand.

Analysts split on what comes next

The analyst community remains divided. JPMorgan's David Perry held his "Neutral" rating and €1,350 price target on 17 August, arguing that despite strong second-quarter results, uncertainty persists around revenue development between 2027 and 2030. Jefferies' Chloe Lemarie struck a more constructive tone, lifting her price target from €1,300 to €1,350 mid-August while reaffirming a buy recommendation.

The share price reflects this ambivalence. At €1,155.40, the stock trades 42 percent below its early-October peak of €2,007 — though it now sits 5.7 percent above its 50-day average of €1,093.54, suggesting short-term stabilisation after a period of technical weakness.

What to watch

The immediate catalyst remains the Boxer signature. Each piece of news around the deal is likely to move the share price disproportionately until the contract is either signed or formally deferred. In the meantime, the steady flow of concrete call-offs — Lithuania, the field hospitals, and whatever follows — offers the clearest evidence that the pipeline is converting into orders. The Bremen presentation and next week's Stockholm seminar will show whether institutional investors are prepared to look past the near-term scepticism and price in the backlog's full potential.